Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of Alrosa approved dividends for 6 months 2023

10/2/23 ALRS

Shareholders of NOVATEK approved dividends for 6 months 2023

10/2/23 NVTK

Nornickel started ore mining at a record depth of almost 2 km

10/2/23 GMKN

UWC Board of Directors appointed a new CEO

10/2/23 UWGN

Developer Samolet enters the Yekaterinburg market

10/2/23 SMLT

Ozon launches its own operating system with VK services

10/2/23 OZON

Kristall distillery wants to IPO by the end of the year

10/2/23 KLVZ

AT&T announced a quarterly dividend

9/29/23 T

Surgutneftegaz reported for 6 months of 2023 by IFRS

9/29/23 SNGS

Surgutneftegaz reported for 6 months of 2023 by RAS

9/29/23 SNGS